RATIONALE: Diagnostic criteria have been established to diagnose MCAS in adults, however, the guidelines for children are unclear. Here we present a case series of children who presented to our multi-disciplinary, allergy/gastroenterology (GI) clinic with symptoms suggestive of MCAS who were found to have laboratory evidence of mast cell activation. METHODS: Children who presented to our clinic between 2014-2018 with a combination of non-IgE mediated adverse food reactions to more than one food, GI complaints, symptoms consistent with MCAS and at least one positive mast cell mediator marker per the adult criteria were included. RESULTS: The cases diagnosed as MCAS included a total of 15 children from 12 months to 17 years of age. All had a history of abdominal pain with at least one other GI symptom and all had at least two symptoms consistent with MCAS. Eighty-seven percent of patients had an elevated mast cell mediator. The urine 2,3-dinor-11beta-prostaglandin F2 alpha (2,3 BPG) was the most common abnormal marker with 40% patients having a level greater than 5205pg/ml creatinine. All patients had improvement of GI symptoms with a combination of H1/H2 blockers and/or oral mast cell stabilizers. CONCLUSIONS: Most of the children in our case series were found to have MCAS according to adult diagnostic criteria. Checking urine mediators and a tryptase level should be considered in children with histories similar to our cohort as not to delay care. Further research is needed to establish diagnostic criteria for MCAS in children. Omalizumab is an off-label subcutaneously administered mast cell stabilizer which is frequently used to treat anaphylaxis. Changes in levels of tryptase, a mediator which marks the activity of the mast cell, affirms the response of omalizumab. We wanted to explore the use of omalizumab in controlling SM. METHODS: This is a retrospective, descriptive case series of 5 patients (n55) being treated with omalizumab for their SM. Patients were eligible if they had bone marrow biopsy confirmed SM, based on the 2016 WHO criteria. Electronic medical records were reviewed by two independent reviewers (CS, CS) to identify SM symptoms and tryptase levels prior to the initiation of ketotifen (< _6 months prior) and again post-initiation (4-8 months post). The Brown anaphylaxis score was used to record severity of anaphylaxis (scores of 3: severe life-threatening reactions; 2: moderate systemic involvement; 1: no systemic involvement). RESULTS: 100% of patients responded to treatment with responses ranging from 17% to 100% improvement in mastocytosis-linked symptoms. Both 2 patients whose tryptase levels were available at baseline and follow-up saw reduction in levels; one patient from 134 ng/mL to 84. 3/5 patients improved from severe anaphylaxis (score of 3) to mild (1). 2 patients remained at moderate (2). CONCLUSIONS: Omalizumab appears to effectively manage SM symptoms as well as lowers tryptase levels. Patients with diagnoses of postural orthostatic tachycardia syndrome (POTS) and hypermobile Ehlers-Danlos syndrome (hEDS) often report symptoms suggestive of mast cell activation. We evaluated the frequency of symptoms suggestive of mast cell activation syndrome (MCAS) in a cohort of patients with confirmed diagnoses of either POTS/ hEDS. METHODS: A retrospective chart review was performed for patients with hEDS and/or POTS from 2008 to mid-2018. Symptoms suggestive of mast cell activation were assessed using the 2018 diagnostic criteria. RESULTS: A total of 31 patients were diagnosed with POTS (Group 1) (2015 Heart Rhythm Society Expert Consensus Statement) and 38 patients with hEDS (Group 2) (March 2017 nosology) and of these, 23 patients had both POTS and hEDS (Group 3). In Groups 1, 2 and 3, 100% had both cutaneous and gastrointestinal involvement. Next in frequency were nasoocular symptoms in 45 -61%; cardiovascular 52 -58%; respiratory 43 -47%; and central nervous system 3 -5%. There was very little variance in the frequency of organ system involvement in these 3 cohorts of patients. Over 95% of patients in all groups reported a significant response to H1 blockers, over 89% to H2 blockers and 80% to mast cell stabilizers. CONCLUSIONS: Symptoms of mast cell activation were present in patients with confirmed diagnoses of POTS alone; with hEDS alone, and both POTS and hEDS. The most dominant manifestations recurring were cutaneous and gastrointestinal. The use of H1 and H2 blockers and mast cell stabilizers were associated with reduction in these symptoms. 
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